IPUBLIC RECORDSEXCHANGERECEIPTSloadinglive·IMONEY TRAILEXCHANGESOURCESverifyinglive·IDATA SOURCESEXCHANGEFILINGSpublic recordslive·IPUBLIC RECORDSEXCHANGERECEIPTSloadinglive·IMONEY TRAILEXCHANGESOURCESverifyinglive·IDATA SOURCESEXCHANGEFILINGSpublic recordslive·
← Leaderboard
PODD
Ticker

PODD

Congressional Trades
17
by 2 members
Ticker Intelligence Brief

Who in Congress traded PODD, when, and what happened after?

A ticker-first view for retail/data users: latest disclosure, largest range, disclosure lag, party flow, contracts, lobbying, and source-linked receipts.

Latest receipt
Ro Khanna
SELL · 2026-05-27
Largest range
$250K – $500K
Tina Smith
Slowest filing
39d
Ro Khanna
Best vs SPY
0.1%
Ro Khanna
Buys
5
29%
Sells
7
41%
Total Volume
$1.3M
midpoint
Unique Traders
2
members

Party Breakdown

Democrats17 · 100%
Republicans0 · 0%

Party Trading Divergence

Democrat vs. Republican buy / sell pressure by monthMODERATE

Bar length = total trades. Color = net sentiment — green = net buying, red = net selling. Months with no activity hidden.

Democrat ←
Month
→ Republican
0▲2▼
Apr '24
—
0▲2▼
Nov '24
—
1▲
Aug '25
—
1▲1▼
Feb '26
—
2▲2▼
Apr '26
—
1▲4▼
May '26
—
Democrats5▲11▼Net sellers
vs
Republicans0▲0▼Neutral
Net buyingNet selling⚡ Party split

💼 Lobbying Filings

all →
  • 2026-04-20$140K
    INSULET CORPORATION
    Issues related to the disease of diabetes, diabetes therapies, automated insulin delivery devices, and management of the disease of diabetes. Issues related to medical devices and medical device technologies. Issues related to Pharmacy Benefit Manager (PBM) reform proposals, PBM transparency and potential PBM proposals related to talks of future budget reconciliation package. Issues related to the reintroduction of the DIABETES Act (S.4037) in the 119th Congress. Issues related to artificial intelligence (AI) and predictive algorithms in medical devices and medical device technology. Issues related to tariffs and trade and the Sec. 232 Tariff investigation related to Medical Devices. Issues related to Local Coverage Determination revisions specifically in pathways for Continuous Glucose Monitors (CGM). Issues related to National Coverage Determination revisions specifically in reference to durable infusion insulin pumps. Issues related to Prior Authorizations in Medicare Advantage plan
  • 2026-04-20$60K
    INSULET CORPORATION
    General education on diabetes care. General education about Insulet.
  • 2026-01-19$140K
    INSULET CORPORATION
    Issues related to the disease of diabetes, diabetes therapies, automated insulin delivery devices, and management of the disease of diabetes. Issues related to medical devices and medical device technologies. Issues related to Pharmacy Benefit Manager (PBM) reform proposals, PBM transparency and potential PBM proposals related to budget reconciliation package. Issues related to the reintroduction or possible reintroduction of the DIABETES Act in the 119th Congress. Issues related to artificial intelligence (AI) and predictive algorithms in medical devices and medical device technology. Issues related to tariffs and trade. Issues related to Local Coverage Determination revisions specifically in pathways for Continuous Glucose Monitors (CGM). Issues related to National Coverage Determination revisions specifically in reference to insulin pumps. Issues related to Prior Authorizations in Medicare Advantage plans. Issues related to support of Improving Seniors' Timely Access to Care Act. Is
  • 2026-01-17$50K
    INSULET CORPORATION
    General education on diabetes care. General education about Insulet.
  • 2025-10-17$110K
    INSULET CORPORATION
    Issues related to the disease of diabetes, diabetes therapies, automated insulin delivery devices, and management of the disease of diabetes. Issues related to medical devices and medical device technologies. Issues related to Pharmacy Benefit Manager (PBM) reform proposals, PBM transparency and potential PBM proposals related to budget reconciliation package. Issues related to the reintroduction or possible reintroduction of the DIABETES Act in the 119th Congress. Issues related to artificial intelligence (AI) and predictive algorithms in medical devices and medical device technology. Issues related to tariffs and trade. Issues related to Local Coverage Determination revisions specifically in pathways for Continuous Glucose Monitors (CGM). Issues related to Prior Authorizations in Medicare Advantage plans. Issues related to support of Improving Seniors' Timely Access to Care Act. Issues related to CMS notice of proposed rule, DMEPOS Home Health Rule.
  • 2025-10-12$50K
    INSULET CORPORATION
    General education on diabetes care. General education about Insulet.
  • 2025-07-30$40K
    INSULET CORPORATION
    General education on diabetes care. General education about Insulet.
  • 2025-07-21$130K
    INSULET CORPORATION
    Issues related to the disease of diabetes, diabetes therapies, automated insulin delivery devices, and management of the disease of diabetes. Issues related to medical devices and medical device technologies. Issues related to Pharmacy Benefit Manager (PBM) reform proposals, PBM transparency and potential PBM proposals related to budget reconciliation package. Issues related to the reintroduction or possible reintroduction of the DIABETES Act in the 119th Congress. Issues related to artificial intelligence (AI) and predictive algorithms in medical devices and medical device technology. Issues related to tariffs and trade. Issues related to Local Coverage Determination revisions specifically in pathways for Continuous Glucose Monitors (CGM). Issues related to Prior Authorizations in Medicare Advantage plans. Issues related to support of Improving Seniors' Timely Access to Care Act.
  • 2025-07-21$0
    INSULET CORPORATION
    General education on diabetes care. General education about Insulet.
  • 2025-04-17$40K
    INSULET CORPORATION
    Issues related to the disease of diabetes, diabetes therapies, automated insulin delivery devices, and management of the disease of diabetes. Issues related to medical devices and medical device technologies. Issues related to Pharmacy Benefit Manager (PBM) reform proposals, PBM transparency and potential PBM proposals related to budget reconciliation package. Issues related to the reintroduction or possible reintroduction of the DIABETES Act in the 119th Congress. Issues related to artificial intelligence (AI) and predictive algorithms in medical devices and medical device technology. Issues related to tariffs and trade. Issues related to Local Coverage Determination revisions specifically in pathways for Continuous Glucose Monitors (CGM).

Congressional Momentum

buy vs. sell pressureDISTRIBUTING

Score 0–100: above 50 = net buying pressure, below 50 = net selling. Signal based on last 90 days.

Last 30 Days
▼0
0 buys1 total1 sell
$0 buys · $8K sells
Last 90 Days
▼3
3 buys9 total6 sells
$24K buys · $716K sells
All-Time
▼3
5 buys17 total12 sells
$40K buys · $1.3M sells
Cumulative Net Position (buy vol − sell vol)
-$1.2M
2020-0317 trades plotted2026-05

Timing Fingerprint

filing delay vs. excess return over SPY · 15 tradesCongress avg -22.1% vs SPY

Each dot = one disclosed trade. X-axis = days between trade and STOCK Act filing.Y-axis = return above (or below) SPY over the subsequent holding window. Upper-right = late filers who beat the market.

LATE + BEAT SPY0 tradesQUICK + BEAT SPY1 tradesQUICK + TRAILEDLATE + TRAILED-54%-27%0%+27%+54%median 17d0d10d20d30dRo Khanna (D) · 2026-05-27 · sell · 13d delay · +0.1% vs SPY · $8KRo Khanna (D) · 2026-05-15 · sell · 25d delay · -2.4% vs SPY · $8KTina Smith (D) · 2026-05-07 · sell · 4d delay · -7.7% vs SPY · $175KTina Smith (D) · 2026-05-07 · sell · 3d delay · -11.4% vs SPY · $175KRo Khanna (D) · 2026-05-01 · buy · 39d delay · -20.6% vs SPY · $8KTina Smith (D) · 2026-04-29 · partial_sell · 12d delay · -10.2% vs SPY · $175KTina Smith (D) · 2026-04-29 · partial_sell · 11d delay · -10.7% vs SPY · $175KRo Khanna (D) · 2026-04-24 · buy · 17d delay · -24.9% vs SPY · $8KRo Khanna (D) · 2026-04-13 · buy · 28d delay · -32.4% vs SPY · $8KRo Khanna (D) · 2026-02-24 · sell · 13d delay · -24.5% vs SPY · $8KRo Khanna (D) · 2026-02-17 · buy · 20d delay · -25.5% vs SPY · $8KRo Khanna (D) · 2025-08-04 · buy · 36d delay · -45.4% vs SPY · $8KRo Khanna (D) · 2024-11-15 · sell · 20d delay · -47.0% vs SPY · $8KRo Khanna (D) · 2024-11-12 · sell · 23d delay · -48.8% vs SPY · $8KTina Smith (D) · 2024-04-04 · partial_sell · 15d delay · -20.1% vs SPY · $75KFiling Delay (days)Excess Return vs SPY
7% of trades beat SPYavg excess -22.1%avg delay 19d5 buys10 sellsBuySellOther· dot size ∝ trade size

Trade Activity Timeline

Congressional buys & sells by month · last 7 months w/ activity

20/03
24/04
24/11
25/08
26/02
26/04
26/05
BuysSellsOtherHigh-volume month

Who Moved First

each row = one member · sorted by earliest disclosed trade
1 buyers ·2 sellers
202420252026DTina Smith7×2020-03-17 · partial_sell · $375K2024-04-04 · partial_sell · $75K2024-04-04 · partial_sell · $75K2026-04-29 · partial_sell · $175K2026-04-29 · partial_sell · $175K2026-05-07 · sell · $175K2026-05-07 · sell · $175KDRo Khanna10×2024-11-12 · sell · $8K2024-11-15 · sell · $8K2025-08-04 · buy · $8K2026-02-17 · buy · $8K2026-02-24 · sell · $8K2026-04-13 · buy · $8K2026-04-24 · buy · $8K2026-05-01 · buy · $8K2026-05-15 · sell · $8K2026-05-27 · sell · $8K
BuySellOtherDot size ∝ trade size · top 2 most-active traders shown

Seasonal Rhythm

Congress buy/sell pressure by month & year

Each cell = one calendar month. Green = net Congress buying, red = net selling. Intensity ∝ consensus strength. Hover for details.

JanFebMarAprMayJunJulAugSepOctNovDec20262026-01: 0▲ 0▼2026-02: 1▲ 1▼ · $0.0M22026-03: 0▲ 0▼2026-04: 2▲ 2▼ · $0.4M42026-05: 1▲ 4▼ · $0.4M52026-06: 0▲ 0▼2026-07: 0▲ 0▼2026-08: 0▲ 0▼2026-09: 0▲ 0▼2026-10: 0▲ 0▼2026-11: 0▲ 0▼2026-12: 0▲ 0▼20252025-01: 0▲ 0▼2025-02: 0▲ 0▼2025-03: 0▲ 0▼2025-04: 0▲ 0▼2025-05: 0▲ 0▼2025-06: 0▲ 0▼2025-07: 0▲ 0▼2025-08: 1▲ 0▼ · $0.0M12025-09: 0▲ 0▼2025-10: 0▲ 0▼2025-11: 0▲ 0▼2025-12: 0▲ 0▼20242024-01: 0▲ 0▼2024-02: 0▲ 0▼2024-03: 0▲ 0▼2024-04: 0▲ 2▼ · $0.2M22024-05: 0▲ 0▼2024-06: 0▲ 0▼2024-07: 0▲ 0▼2024-08: 0▲ 0▼2024-09: 0▲ 0▼2024-10: 0▲ 0▼2024-11: 0▲ 2▼ · $0.0M22024-12: 0▲ 0▼20202020-01: 0▲ 0▼2020-02: 0▲ 0▼2020-03: 0▲ 1▼ · $0.4M12020-04: 0▲ 0▼2020-05: 0▲ 0▼2020-06: 0▲ 0▼2020-07: 0▲ 0▼2020-08: 0▲ 0▼2020-09: 0▲ 0▼2020-10: 0▲ 0▼2020-11: 0▲ 0▼2020-12: 0▲ 0▼
Net buyingNet sellingNo trades · number = trade count
Peak buy month: Apr · Peak sell month: Apr

Congressional Conviction Timeline

net positioning · alpha track recordBEARISH
5 buys12 sellscumulative α -148.9%7mo tracked
Monthly Net Flow (Buys − Sells)
+3-302020-03: -1 net (0B / 1S)2024-04: -2 net (0B / 2S)2024-11: -2 net (0B / 2S)2025-08: +1 net (1B / 0S)2026-02: 0 net (1B / 1S)2026-04: 0 net (2B / 2S)2026-05: -3 net (1B / 4S)Mar 20Apr 24Nov 24Aug 25Feb 26Apr 26May 26
Cumulative Excess Return on Congressional Buys vs SPY
-148.9%0%-149%0%

All Disclosed Trades

DateMemberActionAmountFiling DelayReceipt
2026-05-27DRo KhannaSELL$1K – $15K13dreceipt →
2026-05-15DRo KhannaSELL$1K – $15K25dreceipt →
2026-05-01DRo KhannaBUY$1K – $15K39dreceipt →
2026-05-07DTina SmithSELL$100K – $250K4dreceipt →
2026-04-29DTina SmithPARTIAL_SELL$100K – $250K12dreceipt →
2026-04-24DRo KhannaBUY$1K – $15K17dreceipt →
2026-04-13DRo KhannaBUY$1K – $15K28dreceipt →
2026-05-07DTina SmithSELL$100K – $250K3dreceipt →
2026-04-29DTina SmithPARTIAL_SELL$100K – $250K11dreceipt →
2026-02-24DRo KhannaSELL$1K – $15K13dreceipt →
2026-02-17DRo KhannaBUY$1K – $15K20dreceipt →
2025-08-04DRo KhannaBUY$1K – $15K36dreceipt →
2024-11-15DRo KhannaSELL$1K – $15K20dreceipt →
2024-11-12DRo KhannaSELL$1K – $15K23dreceipt →
2024-04-04DTina SmithPARTIAL_SELL$50K – $100K16dreceipt →
2024-04-04DTina SmithPARTIAL_SELL$50K – $100K15dreceipt →
2020-03-17DTina SmithPARTIAL_SELL$250K – $500K1259dreceipt →